These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 22235841

  • 1. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
    Cazzola M, Paggiaro P, Palange P, Bjermer L, Ausin P, Carlsson LG, Ekelund J, Lotvall J.
    Clin Drug Investig; 2012 Mar 01; 32(3):147-55. PubMed ID: 22235841
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.
    Drugs; 2008 Mar 01; 68(14):1975-2000. PubMed ID: 18778120
    [Abstract] [Full Text] [Related]

  • 3. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A, Szalai Z, Pullerits T, Radeczky E.
    Respirology; 2007 Sep 01; 12(5):732-9. PubMed ID: 17875063
    [Abstract] [Full Text] [Related]

  • 4. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug 01; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

  • 5. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF, Timmer W, Sagkriotis A, Viel K.
    Chest; 2008 Aug 01; 134(2):255-262. PubMed ID: 18403672
    [Abstract] [Full Text] [Related]

  • 6. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
    Kottakis J, Cioppa GD, Creemers J, Greefhorst L, Lecler V, Pistelli R, Overend T, Till D, Rapatz Gn, Le Gros V, Bouros D, Siafakas N.
    Can Respir J; 2002 Aug 01; 9(2):107-15. PubMed ID: 11972164
    [Abstract] [Full Text] [Related]

  • 7. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C, Polanowski T, Larsson T, Borgström L, Edsbäcker S, Harrison TW.
    Respir Res; 2009 Oct 31; 10(1):104. PubMed ID: 19878590
    [Abstract] [Full Text] [Related]

  • 8. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 31; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 9. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K, Janicki S, Jörres RA, Magnussen H.
    Eur Respir J; 2002 May 31; 19(5):865-71. PubMed ID: 12030726
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
    Cazzola M, Mantero A, Santus P, Carlucci P, Mondoni M, Bosotti L, Centanni S.
    Pulm Pharmacol Ther; 2007 May 31; 20(3):258-64. PubMed ID: 16600647
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results.
    Bogdan MA, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M.
    BMC Pulm Med; 2011 Nov 15; 11():51. PubMed ID: 22085439
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
    Aalbers R.
    Clin Drug Investig; 2010 Nov 15; 30(7):439-51. PubMed ID: 20528000
    [Abstract] [Full Text] [Related]

  • 19. Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.
    Scott LJ.
    Drugs; 2012 Feb 12; 72(3):395-414. PubMed ID: 22316354
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.